Olema Pharmaceuticals Stock Falls as Pivotal Breast Cancer Data Pushed Into 2027
Olema Pharmaceuticals Inc. (NASDAQ:OLMA) shares are trading lower on Tuesday as the company completed enrollment in its pivotal Phase 3 OPERA-01 trial, with top-line data now expected in the first quarter of 2027.
Additionally, the company presented initial Phase 1 clinical data for OP-3136 at the 2026 ASCO Annual Meeting, showcasing its ongoing commitment to developing targeted therapies for women’s cancers.
The company reported cash, cash equivalents, and marketable securities as of June 30, 2026, of $461.1 million.
Net loss for the second quarter was $63.2 million, as compared to $43.8 million a year ago, related to higher spending on clinical development and research and corporate-related activities related to late-stage clinical trials for palazestrant and the advancement of OP-3136.
OLMA Technical Analysis: Key Support, Resistance And Momentum
Currently, Olema is trading at $10.97, significantly below its 20-day simple moving average (SMA) of $11.56, which is about 9.6% lower.
The stock is also trading 7.3% below its 50-day SMA of $11.27, indicating a bearish trend. The moving average convergence divergence (MACD) is below its signal line, suggesting momentum is fading and could lead to further declines unless the stock can reclaim that baseline.
- Key Resistance: $11.50 — a nearby level where rebounds can stall, aligning with the 50-day SMA.
- Key Support: $9.00 — a level where buyers previously stepped in, close to the 52-week low zone.
Analyst Consensus & Recent Actions: The stock carries a Buy rating with an average price forecast of $43.00. Recent analyst moves include:
- HC Wainwright & Co.: Buy (Lowers Forecast to $36.00) (August 11)
- Guggenheim: Buy (Lowers Forecast to $35.00) (May 13)
OLMA Stock Price Activity: Olema Pharmaceuticals shares were down 12.90% at $10.40 at the time of publication on Tuesday, according to Benzinga Pro data.
Photo: Shutterstock